The authors describe the case of a 59-year-old woman, treated for breast cancer by mastectomy and chemotherapy 13 years before her death. Eleven years later she was treated successfully by gastric resection and chemotherapy for gastric cancer. In the last five months, the patient presented dyspnoea, leucopenia, hydropericardium and thoracic fluid both sides. In vivo the origin of these symptoms has not been discovered, neither by cytology nor by pleural biopsy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
An International Lymphoma Radiation Oncology Group study of radiotherapy for bilateral indolent orbital adnexal lymphomas.
Int J Radiat Oncol Biol Phys
March 2025
TBC.
Purpose/objectives: Radiotherapy (RT) is curative for the majority of patients with primary indolent orbital adnexal lymphoma (IOAL). Some reports suggest inferior outcomes for bilateral IOAL, leading to uncertainty regarding optimal management for this presentation. This multicentre, retrospective study evaluated long-term outcomes of bilateral IOAL patients treated with radiotherapy alone.
View Article and Find Full Text PDFTalicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Lancet Haematol
March 2025
Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India. Electronic address:
Background: In low-income and middle-income counties (LMICs), the outcome of relapsed or refractory B-cell malignancies is poor due to the absence of effective therapies. We report the results of a phase 1/2 study of a novel humanised anti-CD19 4-1BB chimeric antigen receptor (CAR) T-cell therapy, talicabtagene autoleucel, for patients with relapsed or refractory B-cell malignancies.
Methods: This open-label, multicentre, phase 1/2 study was done at six tertiary cancer centres in India.
Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.
Blood
March 2025
the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome, and the overall survival of adult patients is poor. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, has shown promise in treating HLH and exerts synergistic effects when combined with dexamethasone. Our pilot study preliminarily demonstrated that the combination of ruxolitinib and dexamethasone (the Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult HLH patients.
View Article and Find Full Text PDFBiology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.
Blood
March 2025
Weill Cornell Medicine, New York, New York, United States.
Follicular lymphoma (FL) represents a heterogeneous group of B-cell neoplasms with distinct genetic, epigenetic, microenvironmental, and clinical features. It is the most prevalent indolent non-Hodgkin lymphoma, characterized by a relapsing course and risk of transformation to aggressive diffuse large B-cell lymphoma. Recent advances in high-throughput sequencing, spatial transcriptomics, and imaging technologies uncovered genetic, epigenetic, and immunogenetic features underpinning FL, offering insights into its biology and potential therapeutic vulnerabilities.
View Article and Find Full Text PDFACEi and ARBs as Primary Prevention of Cancer Therapy-Related Cardiomyopathy in Patients Undergoing Chemotherapy with Anthracyclines: A Systematic Review and Meta-Analysis.
Cardiol Ther
March 2025
Division of Cardiology, Christus Good Shepherd Medical Center, Longview, TX, USA.
Introduction: Anthracyclines treat a myriad of malignancies; however, they are known to lead to cancer therapy-related cardiomyopathy (CTRC). Randomized controlled trials (RCTs) evaluating the role of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in primary prevention of CTRC have yielded mixed results.
Methods: A systematic search of MEDLINE, Cochrane, and Scopus databases was performed to identify RCTs that evaluated outcomes in patients receiving anthracyclines and ACEi or ARBs versus control.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!